Helio Genomics appoints Eric Ariazi, Ph.D. as Chief Development Officer
Helio Genomics announced the appointment of Eric A. Ariazi, Ph.D., as Chief Development Officer.
Dr. Ariazi is a translational cancer biologist experienced in precision oncology, epigenetics, and assay development, and brings to Helio over 25 years of experience encompassing basic, translational, and clinical settings to advance cancer research and liquid biopsy testing to improve patient outcomes.
Prior to joining Helio, Dr. Ariazi was the Founder & Principal Consultant of Biomarker Strategy Consulting, LLC, where he provided expertise in epigenetic drug development and next-generation sequencing assay development to detect and monitor disease from blood. Eric has already played an integral role in critical review of laboratory protocols and audited laboratory processes involved in cfDNA methylation sequencing to detect liver cancer for Helio Genomics. Prior to consulting, he was a Senior Principal Scientist in the Department of Translational Medicine at ORIC Pharmaceuticals, where he led the development, execution, and analysis of predictive and pharmacodynamic biomarkers for clinical-stage compounds. As an early employee at Freenome, Eric was the fourth employee after its three co-founders, and Freenomes first scientific hire. He held positions of increasing responsibilities, and spearheaded assay development of targeted cfDNA methylation sequencing, which has become the centerpiece of Freenomes blood-based multi-omic cancer detection platform. Before these positions in industry, Eric was an Assistant Research Professor at Fox Chase Cancer Center, primarily researching endocrine therapy resistance in breast cancer. He has published numerous articles in peer-reviewed journals and has several issued patents and patent applications. Eric holds a Ph.D. with a double major in Cellular and Molecular Biology and Human Cancer Biology from the University of Wisconsin Carbone Cancer Center and completed his Postdoctoral Research Fellowship in Molecular Oncology at the McArdle Laboratory for Cancer Research in Madison, Wisconsin.
